Concourse Financial Group Securities, Inc. Prometheus Biosciences, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$103.46 - $126.29 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$36.06 - $117.21 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$28.17 - $59.01 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$22.39 - $38.94 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$30.13 - $50.0 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$22.28 - $39.54 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$20.89 - $26.96 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$16.8 - $29.65 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$16.51 - $25.29 $0 - $0
0 New
0 $0

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email